{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T04:31:59Z","timestamp":1766377919306},"reference-count":0,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TCRM"],"DOI":"10.2147\/tcrm.s73559","type":"journal-article","created":{"date-parts":[[2015,6,23]],"date-time":"2015-06-23T19:54:40Z","timestamp":1435089280000},"page":"979","source":"Crossref","is-referenced-by-count":4,"title":["A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia"],"prefix":"10.2147","author":[{"given":"Simon","family":"Rule","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Tucker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2015,6]]},"container-title":["Therapeutics and Clinical Risk Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=25590","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,10,30]],"date-time":"2016-10-30T18:39:39Z","timestamp":1477852779000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.dovepress.com\/a-critical-appraisal-of-ibrutinib-in-the-treatment-of-mantle-cell-lymp-peer-reviewed-article-TCRM"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":0,"URL":"https:\/\/doi.org\/10.2147\/tcrm.s73559","relation":{},"ISSN":["1178-203X"],"issn-type":[{"value":"1178-203X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6]]}}}